PULMOPHARMA ApS: Financial statements 2022
CVR: 36428023
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
PULMOPHARMA ApS (CVR 36428023) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -56,496 and a net result of DKK -62,830 compared with DKK -93,103 the year before. Equity in the 2022 report amounted to DKK 3,448,885. The solvency ratio was 69.6%.
- Gross Profit
- DKK -56,496
- Profit/Loss
- DKK -62,830
- Equity
- DKK 3,448,885
- Total Assets
- DKK 4,953,467
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -56 t. | -63 t. | 3.4 mio. | 0 |
| 2021 | - | -80 t. | -93 t. | 3.5 mio. | 0 |
| 2020 | - | -1 t. | -19 t. | -395 t. | 1 |
| 2019 | - | -9 t. | -26 t. | -376 t. | - |
| 2018 | - | -292 t. | -224 t. | -350 t. | - |
Official annual report
Keep an eye on PULMOPHARMA ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
PULMOPHARMA ApS has published its annual report for 2021. Gross profit came to DKK -80,380, and the net result was DKK -93,103.
About PULMOPHARMA ApS
PULMOPHARMA ApS is a Danish company of the type Anpartsselskab based in Ebeltoft, founded in 2014. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named PULMOPHARMA IVS. The management consists of Dan Mønster Nielsen. The board consists of Torben Ballegaard Sørensen (chair), Dan Mønster Nielsen, Per Bendix Jeppesen and Peter Frithjof Bang. The company's owners include PETER BANG HOLDING ApS, LARS NYENSTAD ApS and BENDIX-HOLDING ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -49,353 and a net result of DKK -49,353 compared with DKK -20,499 the year before. Equity in the 2025 report amounted to DKK 11,436,934.